March 14, 2025 · Form 4 insider transaction
Patel Naimish bought 46,667 shares of CRISPR Therapeutics AG at $0.00 per share, a transaction worth N/A. The trade was recorded as grant or award and disclosed on an SEC Form 4, filed 4 days after the transaction.
This option was granted on March 14, 2025 with respect to 46,667 Common Shares. 100% of the shares will vest in 48 equal monthly installments, with the first vesting date of April 14, 2025.